U.S. Markets open in 8 hrs 30 mins

Today’s Research Reports on Acerus Pharmaceuticals, TSO3, BELLUS Health and ImmunoVaccine

NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Acerus Pharmaceuticals Corp.
https://rdinvesting.com/news/?ticker=ASP.TO

TSO3 Inc.
https://rdinvesting.com/news/?ticker=TOS.TO

BELLUS Health Inc.
https://rdinvesting.com/news/?ticker=BLU.TO

ImmunoVaccine Inc.
https://rdinvesting.com/news/?ticker=IMV.TO

Acerus Pharmaceuticals' stock moved 1.85% lower Wednesday, to close the day at $0.27. The stock recorded a trading volume of 47,000 shares, which was below its three months average volume of 236,750 shares. In the last year, Acerus Pharmaceuticals' shares have traded in a range of 0.10 - 0.52. The share price has gained 165.00% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.27 is greater than its 200-day moving average of $0.24. Shares of Acerus Pharmaceuticals have fallen approximately 8.62 percent year-to-date.

Access RDI's Acerus Pharmaceuticals Corp. Research Report at:
https://rdinvesting.com/news/?ticker=ASP.TO

On Wednesday, shares of TSO3 recorded a trading volume of 81,678 shares, which was below the three months average volume of 248,869 shares. The stock ended the day 0.99% lower at 1.00. The stock is currently trading 69.70% below its 52-week high with a 52-week trading range of 0.94 - 3.30. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.23 is below its 200-day moving average of $2.17. Shares of TSO3 have fallen approximately 61.69 percent year-to-date.

Access RDI's TSO3 Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TOS.TO

BELLUS Health's stock moved 4.08% lower Wednesday, to close the day at $0.47. The stock recorded a trading volume of 66,002 shares, which was below its three months average volume of 258,459 shares. In the last year, BELLUS Health's shares have traded in a range of 0.27 - 0.55. The share price has gained 74.07% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.44 is greater than its 200-day moving average of $0.41. Shares of BELLUS Health have gained approximately 27.03 percent year-to-date.

Access RDI's BELLUS Health Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLU.TO

On Wednesday, shares of ImmunoVaccine recorded a trading volume of 46,725 shares, which was below the three months average volume of 102,995 shares. The stock ended the day 3.63% lower at 1.86. The share price has gained 86.00% from its 52-week low with a 52-week trading range of 1.00 - 2.55. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $1.97 is greater than its 200-day moving average of $1.79. Shares of ImmunoVaccine have fallen approximately 20.85 percent year-to-date.

Access RDI's ImmunoVaccine Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMV.TO

Our Actionable Research on Acerus Pharmaceuticals Corp. (TSX:ASP.TO), TSO3 Inc. (TSX:TOS.TO), BELLUS Health Inc. (TSX:BLU.TO) and ImmunoVaccine Inc. (TSX:IMV.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com